%0 Journal Article
%A Kaulen, Leon
%A Martinez-Lage, Maria
%A Abramson, Jeremy S
%A Karschnia, Philipp
%A Doubrovinskaia, Sofia
%A Shankar, Ganesh M
%A Choi, Bryan D
%A Ramundo, Christopher M
%A Ehret, Felix
%A Barnes, Jeffrey A
%A El-Jawahri, Areej
%A Hochberg, Ephraim P
%A Johnson, P Connor
%A Soumerai, Jacob D
%A Plotkin, Scott R
%A Batchelor, Tracy T
%A Wick, Wolfgang
%A Maus, Marcela V
%A Chen, Yi-Bin
%A Frigault, Matthew J
%A Dietrich, Jorg
%T Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy.
%J Blood
%V 146
%N 16
%@ 0006-4971
%C Washington, DC
%I American Society of Hematology
%M DKFZ-2025-02156
%P 1902 - 1913
%D 2025
%Z #EA:B320#
%X Tumor inflammation-associated neurotoxicity (TIAN) was recently proposed as a unique complication of immunotherapy in patients with brain tumor. Here, we report a first comprehensive characterization of TIAN in patients with central nervous system (CNS) lymphoma (CNSL) treated with CD19-directed chimeric antigen receptor (CD19-CAR) T cells. TIAN occurred in 10 of 56 (17.9
%K Humans
%K Male
%K Female
%K Middle Aged
%K Antigens, CD19: immunology
%K Immunotherapy, Adoptive: adverse effects
%K Central Nervous System Neoplasms: therapy
%K Central Nervous System Neoplasms: immunology
%K Central Nervous System Neoplasms: pathology
%K Aged
%K Adult
%K Neurotoxicity Syndromes: etiology
%K Neurotoxicity Syndromes: therapy
%K Lymphoma: therapy
%K Lymphoma: immunology
%K Lymphoma: pathology
%K Receptors, Chimeric Antigen: immunology
%K Treatment Outcome
%K Cytokine Release Syndrome: etiology
%K Antigens, CD19 (NLM Chemicals)
%K Receptors, Chimeric Antigen (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40663771
%R 10.1182/blood.2025028964
%U https://inrepo02.dkfz.de/record/305427